Nottingham, UK-based Contract Research Organisation (CRO) XenoGesis has appointed Sabrina Mogle as a consultant to spearhead its business development strategy in the US.
Mogle has extensive experience in business and corporate development and strategy having spent her career in the biotechnology and pharmaceutical industry.
With more than 12 years of experience she has a wealth of knowledge and understanding of drug development and regulatory affairs in both the US and Europe.
Mogle spent the first half of her career in contract research starting in discovery immunology and working with large molecules and therapeutics. She then moved into the small molecule arena focusing on ADME and toxicology.
In more recent roles she has focused on regulatory affairs strategies and submissions for rare diseases and oncology.
Mogle is also co-founder and CEO of RareMoon Consulting, a firm specialising in non-clinical development and regulatory affairs exclusively for orphan products, and works with biotechnology executives on their preclinical drug development and regulatory strategies.
She gained a Bachelor’s Degree in Molecular Biology from the University of Pittsburgh in 2004.
XenoGesis' Managing Director Richard Weaver said: 'Sabrina’s appointment supports our growth strategy to open up the US market. We already have a number of clients in the US and have identified the opportunity to grow our business further in the US. We are excited to welcome Sabrina to the team and her experience, knowledge and understanding of drug development and regulatory affairs in the US will be a valuable addition to our business.'
Mogle will be based in the East Coast area.
